News >

Denosumab Approved in Europe for Myeloma

Jason M. Broderick @jasoncology
Published: Tuesday, Apr 03, 2018

David M. Reese, MD

David M. Reese, MD
The European Commission has approved denosumab (Xgeva) for the prevention of skeletal-related events (SREs) in adult patients with multiple myeloma, according to Amgen, the developer of the RANK ligand inhibitor.

Based on these findings, the FDA approved denosumab in this setting in January 2018.
Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study [published online February 9, 2018]. Lancet Oncol. doi/10.1016/ S1470-2045(18)30072-X.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x